Floatz logo

Mirvetuximab Soravtansine

Primary Peritoneal Cancer

AbbVieantibody_drug_conjugatePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
69/ 100
Competitive Position
73/ 100

Competitive context

153 Active assets in the Primary Peritoneal Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
GOG Foundation
Phase 3BBB
Carboplatin
University of Washington
Phase 3BBB
Hycamtin
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BBB
Inno-206
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BBB
PEGFILGRASTIM
TORL Biotherapeutics, LLC
Phase 2/3BBB

View all 50 →

Same molecule, other indications

Mirvetuximab Soravtansine is also rated in:

ovarian carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
fallopian tube cancerDormant
BB
Indicative ·
70 / 100
View asset →
peritoneum cancerDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →